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AC = doxorubicin and cyclophosphamide; CAF = cyclophosphamide, doxorubicin and 5-fluorouracil; CEF = cyclophosphamide, epirubicin and 5-
fluorouracil; CMF = cyclophosphamide, methotrexate and 5-fluorouracil; DFS = disease-free survival; EBCTCG = Early Breast Cancer Trialists Col-
laborative Group; ER = oestrogen receptor; FAC = 5-fluorouracil, doxorubicin and cyclophosphamide; FEC = 5-fluorouracil, epirubicin and
cyclophosphamide; LHRH = luteinizing hormone-releasing hormone; OA = ovarian ablation; OS = overall survival; PgR = progesterone receptor;
RR = relative risk; SE = standard error.
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Abstract
Endocrine therapy remains important in premenopausal women with
hormone receptor positive breast cancer. Ovarian ablation, used
alone, is effective in delaying recurrence and increasing survival in
such women. When added to chemotherapy, it is less clear that it is
effective perhaps because of the endocrine ablative effect of
chemotherapy. Trials comparing ovarian ablation with or without
tamoxifen to CMF-type chemotherapy suggest that the endocrine
therapy is equivalent to or better than this chemotherapy in women
whose tumors have estrogen and/or progesterone receptor.
Tamoxifen is also effective in preventing recurrence and prolonging
survival in the adjuvant setting in premenopausal women. While
most of the available data deals with tamoxifen given alone, it
appears to have a similar beneficial effect when added to
chemotherapy in the premenopausal adjuvant setting. Adjuvant
aromatase inhibitors should not be used in premenopausal women.
Introduction
Endocrine therapy, developed over a century ago [1,2],
remains the most effective and the most clearly targeted
form of systemic therapy for breast cancer. Endocrine
treatments work best in women whose tumours are
positive for oestrogen receptor (ER) and/or progesterone
receptor (PgR). As we continue to search for newer
targeted therapies that will shrink cancers effectively with
few undesired side effects, and carry out complex
statistical analyses to identify predictive factors, we should
not forget the first targeted cancer therapy, namely ovarian
ablation (OA) for breast cancer, and the first predictive
factor for treatment of any cancer, the ER.
Premenopausal adjuvant endocrine therapy
Ovarian ablation
For many years adjuvant OA was used and felt to be
helpful, but randomized trials were not done.
Subsequently, a few small randomized trials were
conducted in the 1960s and 1970s. Before the first Early
Breast Cancer Trialists Collaborative Group (EBCTCG) or
Oxford overview was published in 1984 [3], it was
generally believed that these trials showed no benefit for
OA. When the meta-analytic techniques used in the
EBCTCG overview were applied to these small trials,
however, it became apparent that OA was associated with
a reasonably large positive effect on both disease-free
survival (DFS) and overall survival (OS) in node-positive
and node-negative premenopausal women [3–5].
The most recent EBCTCG overview (www.ctsu.ox.ac.uk/
ebctcg/), carried out in September 2000, included updated
information on 4900 women aged under 50 years included
in 15 trials of OA. Only about 1300 of these women were in
trials of OA in the absence of chemotherapy, whereas more
than 3500 were in trials of OA in the presence of
chemotherapy. In this updated analysis there was a clear
separation between the trials of OA versus no treatment in
the absence of chemotherapy and trials of OA plus
chemotherapy versus the same chemotherapy. In the former
trials large and highly significant positive effects of OA
persisted at 15 years in terms of recurrence (59.0% versus
45.6%; difference = 13.4%, standard error [SE] = 3.2),
breast cancer deaths (59.4 versus 49.1%; difference =
10.3%, SE = 3.1), and all deaths (56.7% versus 46.3%;
difference = 10.4%, SE = 3.1). In contrast, the trials of OA
plus chemotherapy versus the same chemotherapy found
no significant difference in terms of recurrence (52.5%
versus 55.8%; difference = –3.2%, SE = 3.6), breast
cancer deaths (47.1% versus 52.4%; difference = –5.3%,
SE = 3.3), or all deaths (46.6 versus 52.1%; difference =
–5.5%, SE = 3.3).
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One randomized trial from Scotland [6], conducted in
premenopausal node-positive and node-negative women,
compared intravenous cyclophosphamide, methotrexate
and 5-fluorouracil (CMF) chemotherapy given every
3 weeks for eight cycles versus ovarian removal. There
was no significant difference between the effects of CMF
and those of ovarian removal on either DFS or OS. Those
with ER levels greater than 100 fmol/mg, however, had
better DFS and OS with ovarian removal, whereas those
with ER levels of under 100 fmol/mg did better with CMF.
Although this CMF chemotherapy schedule is known to
be less effective than standard Bonnadonna day 1 and 8
CMF (cyclophosphamide 100 mg/m2 on days 1–14, and
methotrexate 40 mg/m2 and 5-fluorouracil 600 mg/m2
each given on days 1 and 8, intravenously) [7], that study
does suggest that ovarian removal in women with high
levels of ER may be as effective or more effective than at
least some types of CMF chemotherapy.
Few other studies of this design were done until recently.
An as yet unpublished trial by Ejlertsen and coworkers [8]
was presented at the 1999 Meeting of the American
Society of Clinical Oncology. In that trial 732 pre-
menopausal women, who had ER-positive tumours that
were either node positive and/or whose tumour size was
greater than 5 cm, were randomly assigned to receive OA
by radiation therapy or CMF intravenously for nine cycles.
DFS at 5 years was superior for OA, but OS was
equivalent. We await full publication of these study results.
Luteinizing hormone-releasing hormone analogues
More recently, the development of the luteinizing hormone-
releasing hormone (LHRH) analogues has re-awakened
interest in the use of OA. In one relatively large phase III
trial [9] the LHRH analogue goserelin (Zoladex;
AstraZeneca Canada Inc., Mississauga, Ontario, Canada)
was shown to be as effective as surgical OA in the
treatment of metastatic breast cancer. Recently, four small
studies comparing tamoxifen plus an LHRH analogue
versus an LHRH analogue alone suggested that the
combination may be superior in terms of progression and
OS in the metastatic setting [10]. This suggests that the
combination of an LHRH analogue and tamoxifen might
confer additional benefit over either alone in the adjuvant
setting. Various LHRH analogues (in particular Zoladex)
have now been tested in adjuvant therapy using study
designs that compare Zoladex, tamoxifen, or Zoladex plus
tamoxifen versus chemotherapy in the premenopausal
setting, or that add Zoladex, tamoxifen, or Zoladex plus
tamoxifen to chemotherapy in the same group of women.
In one trial conducted by Jakesz and coworkers [11] 1095
women with stage I and II, ER-positive and/or PgR-
positive breast cancer were randomly assigned to receive
Zoladex plus tamoxifen or CMF chemotherapy. Women
receiving the endocrine therapy had significantly improved
DFS (P < 0.02) but OS was not significantly different
between treatments. In another landmark study, the
ZEBRA (Zoladex Early Breast Cancer Research
Association) trial, conducted by Jonat and coworkers [12],
1640 premenopausal and perimenopausal node-positive
women whose tumours were ER positive or negative were
randomly assigned to receive Zoladex for 2 years or CMF
for six cycles. In ER-positive women DFS and OS were
equivalent, whereas in ER-negative women DFS and OS
were superior in the CMF arm. In both of those trials,
women who became amenorrhoeic following CMF therapy
had better outcomes than those who did not, suggesting
that the endocrine effects of chemotherapy also play a
role in this setting.
Rutqvist [13] has reported but not fully published results
from the Zoladex in Premenopausal Patients trial – a large
randomized 2 × 2 factorial study in which premenopausal
women with early-stage disease were randomly assigned,
after primary surgery, to receive one of the following
treatments: tamoxifen for 2 years; Zoladex (26 monthly
subcutaneous injections); tamoxifen plus Zoladex; and no
endocrine therapy. Some patients electively received
tamoxifen, or not and were randomly assigned to just
Zoladex. The study protocol also permitted the use of
elective adjuvant chemotherapy. A total of 2631 women,
of whom 56% were node negative, were included.
Information regarding ER status was available in 1577
(60%) of the women. At a median follow up of 4.3 years,
fewer recurrences (261 [20%]) were observed among
patients assigned to Zoladex than among those who did
not receive Zoladex (330 [24.9%]; relative hazard = 0.77,
95% confidence interval = 0.66–0.90; P = 0.001). This
effect was most pronounced among those who were
known to have ER positive disease. The benefit with
Zoladex appeared to be somewhat less among those who
received concurrent adjuvant tamoxifen or adjuvant
chemotherapy, but the differences compared with patients
who did not receive such concurrent treatments were not
statistically significant. There were also fewer deaths in
the women allocated to receive Zoladex, although this
finding was not statistically significant (140 [10.7%]
versus 165 [12.4%]; relative hazard = 0.84, 95%
confidence interval = 0.67–1.05; P = 0.12). Thus, in that
study medical castration with Zoladex for 2 years in
premenopausal ER-positive patients produced a
statistically significant benefit in terms of DFS, and a trend
toward improvement in OS, irrespective of concurrent
adjuvant tamoxifen or chemotherapy.
Several other randomized trials [8,14,15] compared CMF
versus ovarian suppression with or without tamoxifen, and
two compared FAC (5-fluorouracil, doxorubicin and cyclo-
phosphamide) or FEC (5-fluorouracil, epirubicin and cyclo-
phosphamide) versus ovarian suppression plus tamoxifen,
all with similar results suggesting equivalence or72
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superiority for the endocrine arm (Table 1). However, with
the development of second- and third-generation
combinations such as cyclophosphamide, epirubicin and
5-fluorouracil (CEF), which is more efficacious than
standard Bonadonna CMF [16], and doxorubicin and
cyclophosphamide (AC) taxol, which produces better
results than AC alone [17], it is unclear what final
conclusions one should draw from studies that compare
‘first-generation’ chemotherapy regimens such as AC or
CMF versus OA by whatever means [18].
The results of another interesting study from the Eastern
Cooperative Oncology Group were presented by
Davidson [19] at the 1999 Meeting of the American
Society of Clinical Oncology. That study compared
cyclophosphamide, doxorubicin and 5-fluorouracil (CAF)
versus CAF plus Zoladex or CAF plus Zoladex and
tamoxifen in 1504 premenopausal node-positive women. It
showed that the addition of tamoxifen to CAF plus Zoladex
was significantly better in terms of DFS (P = 0.01) but not
OS. The addition of Zoladex to CAF resulted only in a
trend toward improvement in DFS (P = 0.10). A
preliminary, hypothesis-generating analysis presented by
Davidson suggested that the addition of Zoladex was
more effective in younger women and/or in women who
did not become postmenopausal as a result of
chemotherapy, whereas the addition of tamoxifen seemed
more effective in older women and/or in women who
became menopausal as a result of their chemotherapy.
This hypothesis remains to be further explored and
substantiated in prospective randomized trials designed to
address this issue.
In the most recent Oxford overview in September 2000
(www.ctsu.ox.ac.uk/ebctcg/), five trials of the LHRH
agonist Zoladex versus not, in 5700 women were
identified. Data on only three of these trials, including
4200 women, were available. In the Eastern Cooperative
Oncology Group trial [19] all patients had received CAF
chemotherapy; in the FCNLCC (Fédération Nationale des
Centres de Lutte contre le Cancer) French trial, all women
received chemotherapy before being randomly assigned
to Zoladex or control; and in the ZIPP trial 1173 out of
2710 women had received elective chemotherapy before
randomization to Zoladex and/or tamoxifen [13]. The 2000
overview has not yet analyzed these trials by dividing
patients into those who received concurrent
chemotherapy and those who did not. However, with
about 5 years of follow up it seems that, overall, goserelin
is associated with significant reduction in recurrence
(73% versus 68.6%; difference = 4.4%, SE = 1.6),
whereas breast cancer deaths and all deaths show only a
trend toward improvement with goserelin (breast cancer
deaths: 86.2% versus 84.1%; difference = 2.1%, SE =
1.2; all deaths: 85.9% versus 83.9%; difference = 2.0%,
SE = 1.2).
It seems that further trials with much larger numbers of
women and events are required. Furthermore, ongoing
analyses in the EBCTCG process of the effects of OA by
whatever means, with women clearly divided into those
who have and those who have not received concurrent
chemotherapy, are needed. It is also important to examine
women receiving chemotherapy who have become
amenorrhoeic in comparison with those who have not. Is
the addition of OA by whatever method perhaps important
only in those women who do not achieve amenorrhoea
following chemotherapy? Prospective randomized trials of
this specific question are currently being considered by
groups around the world (Goldhirsch A, personal
Table 1
Chemotherapy versus ovarian suppression
Study Treatments Results
Scottish [6] CMF versus surgery No difference
Scandinavian [8] CMF versus XRT No difference
ZEBRA [12] CMF versus OS No difference for ER+
IBCSG VIII CMF versus OS No difference for ER+
GROCTA 02 [47] CMF versus OS + tamoxifen No difference
ABCSG 5 [11] CMF versus OS + tamoxifen Better RFS for OS + tamoxifen
French FAC versus OS + tamoxifen No difference
FASG 06 [48] FEC versus OS + tamoxifen No difference
GABG IVA–93 [14] CMF versus goserelin No difference
Wallwiener and coworkers[15] CMF versus leuprolin No difference
CMF, cyclophosphamide, methotrexate and 5-fluorouracil; ER, oestrogen receptor; FAC, 5-fluorouracil, doxorubicin and cyclophosphamide; FEC,
5-fluorouracil, epirubicin and cyclophosphamide; OS, ovarian suppression; XRT, radiotherapy.73
communication). In particular, the Suppression of Ovarian
Function Trial (SOFT) will determine whether OA confers
additional benefit in women who have received current
standard chemotherapy but have not become
amenorrhoeic. This International Breast Cancer Trials
Group trial is now accruing patients actively, with
cooperative participation from the North American
Intergroup and others. The International Breast Cancer
Trials Group has also designed two other trials, which,
together with SOFT, form a suite or group of nested trials.
In the first of these trials, the Tamoxifen/Exemestane Trial
(TEXT), premenopausal women who undergo OA by any
means are being randomly assigned to receive either
tamoxifen or exemestane; the trial will test whether
tamoxifen or an aromatase inhibitor is better once
premenopausal women are made postmenopausal. In the
second trial, the Premenopausal Endocrine-Responsive
Chemotherapy Trial (PERCHE), women who have
received OA and tamoxifen or OA and exemestane are
being randomly assigned to receive chemotherapy or no
chemotherapy. PERCHE will test the concept of whether
chemotherapy confers additional benefit to optimal
adjuvant endocrine therapy in premenopausal women.
Tamoxifen
After tamoxifen was studied in metastatic disease in
postmenopausal [20] and premenopausal women [21], it
was then tested as adjuvant therapy in both post-
menopausal and premenopausal women. The earliest
randomized controlled studies [22–26] were conducted
mainly in postmenopausal node-positive women. Subse-
quent studies [27], however, showed that tamoxifen used
alone was also effective in premenopausal and post-
menopausal node-negative women, producing positive
effects on DFS and OS that were similar in magnitude to
those of chemotherapy in this setting. The first EBCTCG
overview [3] clarified the presence of strong and
consistent improvements in women receiving tamoxifen,
particularly those who were postmenopausal and ER
positive. In the early overview analyses, however, relatively
small numbers of premenopausal women were
randomized in trials of tamoxifen, and most trials were of
1–2 years of therapy. The results of subsequent trials with
5 years of tamoxifen therapy have clarified the magnitude
of the benefit from tamoxifen. In the most recent EBCTCG
tamoxifen overview [28], it was clearly demonstrated that
premenopausal women randomly assigned to receive
5 years of tamoxifen versus no systemic therapy had
substantial DFS and OS benefits. More of the women in
these later trials were selected to be ER and/or PgR
positive, which probably also increased the magnitude of
the effect seen with tamoxifen.
Within the premenopausal group, however, there are still
few data concerning women randomly assigned to receive
chemotherapy or chemotherapy plus tamoxifen. Only 205
such women were included in the most recent Oxford
overview, of whom only 177 were ER positive (Peto R,
personal communication) [29]. In this group of women in
the overview, there was a marginally significant
improvement in DFS and a trend toward improvement in
OS but, because of the relatively small numbers of women
studied, the effects in this subgroup are less certain.
Subsequent to the 1995 Oxford overview, a Danish trial
[30] was published in which 634 premenopausal women
were randomly assigned to receive either tamoxifen
20 mg/day for one year concurrent with CMF, or no
tamoxifen. That study found no benefit overall from the
addition of tamoxifen. This may relate to the short duration
of tamoxifen treatment, because 2 or 5 years is now
believed to be more efficacious, at least in other settings.
However, in this trial there was a nonsignificant trend for
receptor-positive women to benefit from tamoxifen and for
receptor-negative women to do more poorly if given
tamoxifen, in terms of both DFS and OS. The Southwest
Oncology Group also recently reported the results of a
large randomized study [31] in which high-risk, node-
negative, premenopausal and postmenopausal women
were randomly assigned to receive 5 years of tamoxifen or
no further therapy following randomization to receive
chemotherapy with either CAF or CMF. Tamoxifen was
given subsequent to chemotherapy. The data showed that
only receptor positive postmenopausal women achieved
significant benefit from the addition of tamoxifen.
At least three additional trials in which premenopausal
women are randomly assigned to receive chemotherapy or
chemotherapy followed by tamoxifen are currently ongoing
or have recently been completed [32,33] (Bramwell V,
personal communication). In the International Breast
Cancer Study Group 13-93 trial [32], premenopausal
women not considered suitable for endocrine therapy
alone were randomly assigned to receive either AC for
four cycles followed immediately by CMF for three cycles,
or AC for four cycles followed by a gap and then CMF for
three cycles; and in a cross randomization to tamoxifen for
5 years beginning after chemotherapy, or no tamoxifen.
Five-year DFS was significantly improved (72% versus
64%, relative risk [RR] = 0.76; P < 0.005) for tamoxifen in
the entire group of patients and in those who were ER
positive (75% versus 63%, RR = 0.61; P < 0.0001), but
not in women whose tumours were ER low (67% versus
59%, RR = 085; P = 0.29) or absent (62% versus 81%,
RR = 1.95;  P = 0.07). This trial suggests that adding
tamoxifen in women with ER positive disease is beneficial,
but that adding it in women with ER negative disease, may
be detrimental.
Also recently reported was the European Organisation for
Research and Treament of Cancer 01901 trial in pre-
menopausal women with node-positive and node-negative
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disease, who were randomly assigned, following chemo-
therapy with CMF, FAC, FEC, CAF, or CEF, to tamoxifen
for 3 years or no tamoxifen [33]. The findings, presented at
the 2004 European Conference on Clinical Oncology
Meeting, indicate that for the entire group including
premenopausal and postmenopausal women, tamoxifen
was superior with respect to DFS but there was no
difference in OS. The data have not yet been presented by
menopausal status. The National Cancer Institute of
Canada Clinical Trial Group MA.12 trial, which
randomized women after receiving AC, CMF, or CEF to
tamoxifen or placebo for 5 years, will undergo its first analysis
early in 2005 (Bramwell V, personal communication).
In most parts of the world, certainly in North America, it
has become common practice to follow adjuvant
chemotherapy with tamoxifen in ER-positive or PgR-
positive premenopausal women.
Summary
Optimal treatment for premenopausal women remains a
subject for further study. Second-generation adjuvant
chemotherapies such as CEF [16] and AC taxol [17] have
probably become the treatments of choice for pre-
menopausal women at high risk and/or with ER-negative
and PgR-negative disease. However, there are now
considerable data suggesting that OA by surgery,
irradiation, or an LHRH analogue, with or without the
addition of tamoxifen, may represent a viable alternative to
at least first-generation chemotherapies such as CMF or
AC in premenopausal women with ER-positive and/or
PgR-positive early breast cancer and low or intermediate
risk [18]. Tamoxifen used alone was also clearly shown to
be effective as adjuvant therapy in node-negative and
lower risk ER-positive and PgR-positive women, but there
are virtually no data directly comparing its efficacy with
that of chemotherapy or OA in the adjuvant setting. Although
there are considerable preliminary data suggesting that
adding OA and/or tamoxifen to adjuvant chemotherapy in
premenopausal receptor positive women may add some
small benefit, it is unclear how large such additional benefit
may be or even whether a significant benefit may
consistently be achieved. The relative benefit of such therapy
in various subgroups also remains to be clarified.
Use of other predictive factors
Recently, a considerable body of reports has suggested
that women treated with tamoxifen may respond less well
if their tumours over-express neu/erb B-2 antigen.
Although some studies support this contention [34–37],
others do not [38–44]. Of even greater interest is that
some studies have suggested that neu/erb B-2 over-
expressing tumours may be more responsive to other
endocrine agents such as aromatase inhibitors [34], but
once again some analyses of this matter are contradictory
[45]. In addition, the only trial examining the role of
neu/erb B-2 in premenopausal women, that of Love and
coworkers [46], suggests that patients whose tumours
over-express neu/erb B-2 are more likely to respond to
adjuvant treatment with OA and tamoxifen than are
patients whose tumours do not over-express. Thus, it
appears that over-expression of neu/erb B-2 should not be
used as a predictive factor to select endocrine versus
chemotherapy or for particular types of endocrine therapy
at this time. Further studies of the role of neu/erb B-2
over-expression in order to explain and clarify these
contradictory findings are urgently required. Hopefully,
neu/erb B-2 over-expression and other molecular markers
will be useful in the near future as we refine and target
endocrine therapy toward the women who are most likely
to benefit from it.
Conclusion
Endocrine treatment remains important for women in the
adjuvant setting. The exact combination and sequence of
these drugs is still under investigation but more is known
with each passing year. Randomized trials have greatly
clarified the precise role of the more established of these
endocrine agents, but, in addition, a variety of new agents
are currently under development. These include the pure
anti-oestrogens, such as Faslodex, and newer selective
ER modulators such as raloxifene. Results of trials with
these agents are awaited with great interest.
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